Full Judgment Text
Text read from the judgment PDF published on the High Court's eCourts portal, through the
Indian High Court Judgments open data set (Dattam Labs,
CC BY 4.0).
The court's own copy is the authoritative text.
IN THE HIGH COURT AT CALCUTTA
CIVIL APPELLATE JURISDICTION
APPELLATE SIDE
BEFORE :THE HON’BLE JUSTICE SHAMPA SARKAR
&
THE HON’BLE JUSTICE ARJUN RAY MUKHERJEE
MAT 1717 of 2026
with
CAN 1 of 2026
ICHOR Biologics Private Limited
vs.
The State of West Bengal & Ors.
For the Appellant
: Mr. Jaydip Kar, Sr. Adv.,
Mr. Suman Kumar Dutt, Sr. Adv.,
Mr. Soumya Majumder, Sr. Adv.,
Mr. Paritosh Sinha, Adv.,
Mr. Amitava Mitra, Adv.,
Ms. Sumita Shaw, Adv.,
Mr. Sakabda Roy, Adv.
Mr. Naman Agarwal, Adv.,
Ms. Shrestha Datta
For the State
: Mr. Surajit Nath Mitra, Ld. A.G.,
Mr. Billwadal Bhattacharyya, Ld. A.A.G.,
Mr. Srijib Chakraborty, Adv.
Mr. Aditya Mondal, Adv.
For the Respondent Nos. 2
: Ms. Shiv Shankar Banerjee, Adv.,
Mr. Jatinder Singh Dhatt, Adv.
Judgment reserved on
: 05.10.2026
Judgment pronounced on
: 08.10.2026
Shampa Sarkar, J.
1. The appeal arises out of a judgment and order dated September 30,
2026, passed in WPA No. 20748 of 2026. By the impugned judgment,
His Lordship dismissed the writ petition, inter alia, holding that, there
was no illegality on the part of the respondents in rejecting the technical
bid of the appellant as the license which was renewed under Form 26(I)
of the Drugs Rules 1945, had not been approved by the Central License
Approving
Authority,
(hereinafter
referred
to
as
‘the
Approving
Authority’). The renewal of license granted by the State Licensing
Authority (hereinafter referred to as ‘the Licensing Authority’) might not
be approved by the Approving Authority and as such, the tendering
authority rightly considered the certificate issued by the Licensing
Authority to be invalid. The appellant was disqualified at the technical
round only on the ground that the renewed license did not bear the
stamp of approval of the Approving Authority.
2. According to His Lordship, without the approval of the Approving
Authority, the respondents could not accept the license issued by the
Licensing Authority. Allowing the appellant to participate in the financial
bid would be de hors the eligibility criteria. His Lordship considered
clause 4(a) of the eligibility criteria in the tender document and held that
application for renewal and grant of renewal were two separate exercises
under the law. His Lordship having considered the contents of Form
26(I) of the Drug Rules, 1945 (hereinafter referred to as the said Rules)
as also, Rule 68A, Rule 81 and Rule 122F, arrived at a conclusion that
the above mentioned rules provided that, apart from the satisfaction of
the Licensing Authority, the applicant should also fulfil the requirements
under the law for renewal. The Approving Authority was also required to
be satisfied that the applicant was in a position to fulfil the statutory
obligation. The law permitted the Approving Authority to either suspend
or cancel or revoke any license issued by the Licensing Authority.
Participation of the appellant in the tendering process on the basis of
renewal of the license by the State Licensing Authority under Form 26(I),
but without the approval by the Approving Authority was contrary to the
eligibility criteria prescribed by the tendering authority and as such, the
rejection of the bid of the appellant in the technical round was justified.
3. Mr. Kar, learned Senior Advocate for the appellant submitted that the
Licensing Authority issued the certificate of renewal of license for
manufacture of blood products under Form 26(I), read with Rule 122(I)
of the said Rules on June 22, 2026. Such power to renew the license was
vested in the Licensing Authority by Rule 122F of the said Rules. The
second proviso to Rule 122F(1) provided that the application for renewal
of a license which had been issued under Form 28(E) read with Rule
68A, shall be made before expiry of the said license in the prescribed
form mentioned in the Rules, and during pendency of such application,
the applicant could continue to operate the centre or manufacture blood
products or collect or process or test or store such product till orders on
his application were communicated to him. Referring to Rule 68A, Mr.
Kar submitted that a license was to be granted by the Licencing
Authority as per the procedure laid down therein. Such procedure was
followed and the appellant was granted license, duly approved by the
Approving Authority. The license was in force from April 1, 2021 to
March 31, 2026. Before the expiry of the said license, an application was
filed in terms of Rule 122F, under Form 27E, and subsequently, the
Licensing Authority renewed the license and sent it to the Approving
Authority for approval. As the second proviso to sub-Rule 1 of Rule 122F
permitted the appellant to continue the business during pendency of the
application awaiting approval, the question of disqualifying the appellant
did not arise.
4. The notice inviting tender provided that the participant should have a
valid license for manufacturing plasma derived products. The bidder was
required to produce an attested copy of the license for manufacturing
plasma derived products, approved by the Licensing Authority. Mr. Kar
submitted that the Licensing Authority and the Central License
Approving Authority were separate entities under the law. The tender
document did not provide that a license approved by the Central License
Approving Authority should only be considered as a valid license. The
eligibility criteria only prescribed that the bidder should have a valid
license, approved by the Licensing Authority. In this case, the renewed
license was issued by the Licensing Authority in the prescribed form.
The same was pending approval before the Approving Authority for a
substantial span of time. On account of the delay on the part of the
Approving Authority before whom the report and the application had
been forwarded by the Licensing Authority sometime in June 2026, the
appellant could not be put out of business.
5. It was next contended that Rule 122H, specifically provided that an
original license under Form 28E or a renewed license under Form 26(I),
unless sooner suspended or cancelled, should be valid for a period of 5
years on and from the date on which it was granted or renewed. In this
case, the license was valid for a period of 5 years from the date it was
renewed, that is, June 22, 2026. An endorsement of approval by the
Approving Authority was a mere formality unless the Approving
Authority was dissatisfied with the compliances and decided to either
suspend, revoke or cancel the said license. Therefore, the stamp of
approval never mentioned the date. The license stood valid from the date
the Licensing Authority issued the same and not from the date when the
approval was given. If such was the position of law, in that event the
objection that the appellants did not have a valid license until approval
was granted by the Approving Authority, was not sustainable.
6. Referring to Rule 68A of the said Rules, Mr. Kar submitted that the said
rule applied in case of grant of license and not renewal. The Rule 68A
originally applied in respect of renewal of license as well, but by an
amendment of 2017, the applicability of the said rule also in case of
renewal of license, had been omitted. Mr. Kar prayed that the appellant
should be allowed to participate in the financial bidding.
7. Learned Advocate General, State of West Bengal, submitted that the
appellant did not fulfil the eligibility criteria. The appellant was required
to have a valid license. The Licensing Authority had forwarded the
renewed license to the Approving Authority for approval. Unless such
approval was received, the license did not become valid. The Approving
Authority did not act as a mere post office. It had the authority to either
suspend, cancel or revoke such license.
8. Under such circumstances, the contentions of the appellant that the
approval was a mere formality, could not be accepted. The renewed
license did not become valid until and unless the stamp of approval was
affixed by the Approving Authority. The communication dated June 22,
2026 would not have been issued by the Deputy Director 1 cum
Licensing Authority, to the Drug Controller(I), for necessary approval,
unless the said approval was a legal requirement. Reference was made to
Rule 68A sub-Rule 4 of the said Rules in support of the contention that
the Approving Authority, if satisfied that the applicant was in a position
to fulfil the requirements of the rules, could either grant or renew a
license. Thus, even in case of renewal of license, the role of the
Approving Authority was vital and the same was a mandatory provision
under the law. The second proviso to Rule 122F(1) only permitted the
business to continue, but that said proviso did not make an expired
license valid, until approval was granted.
9. Reference was made to Rule 81 of the said rules, in support of the
contention that, the Licensing Authority and the Approving Authority
had a vital role to play in the procedure to be followed for issuance of a
license or for approval, thereof. The learned Advocate General further
submitted that, it would be an absurd proposition that although the
legislature contemplated approval by the Approving Authority, such
approval was not a mandatory requirement under the law and a renewed
license could be treated as a valid one without such approval. It was
submitted that the other bidders had a valid license with the approval
from the Approving Authority.
10. Having considered the rival contentions of the parties, we deem it
necessary to refer to the following provisions under the Rules of 1945.
11. Rule 2 (b) of the said Rules defines Central License Approving Authority
as follows:“2[b] “Central Licence Approving Authority” means the Drugs
Controller, India or the Joint Drugs Controller India or the Deputy
Drugs Controller (India) appointed by the Central Government;]”
12. Rule 21(b) defines Licensing Authority which reads as follows:21.(b) “Licensing Authority” means the authority appointed by the
Central Government to perform the duties of the Licensing Authority
under these Rules and includes any person to whom the powers of a
Licensing Authority may be delegated under Rule 22;
13. Rule 22 is quoted below:“22. The Licensing Authority may with the approval of the Central
Government by an order in writing delegate the power to sign licences
and Registration Certificates and such other powers as may be specified
in the order to any other person under his control.”
14. The law makes a distinction between the Approving Authority and the
‘Licensing Authority’. Part VII of the said Act deals with manufacture for
sale (or distribution) of drugs other than homeopathic medicines. Rule
68A provides for grant of licenses by the Approving Authority. The said
provision is quoted below:“68A. Grant 3[xxx] of Licences by the Central Licence
Approving Authority. —(1) Notwithstanding anything contained
in this Part, on and from the commencement of the Drugs and
Cosmetics (9th Amendment) Rules, 1992, a licence for the
manufacture for sale or distribution of drugs as specified from
time to time by the Central Government by notification in the
Official Gazette, for the purpose of this rule, shall be granted 4[xxx]
by the Central Licence Approving Authority (appointed by the
Central Government):]
Provided that the application for the grant 4[xxx] of such licence
shall be made to the Licensing Authority.
(2) On receipt of the application for grant 4[xxx] of a licence, the
Licensing Authority shall—
(i) verify the statement made in the application form;
(ii) cause the manufacturing the testing establishment to be
inspected in accordance with the provisions of Rule 79; and
5[xxx]
(3) If the Licensing Authority is satisfied that the applicant is in a
position to fulfil the requirements laid down as in these rules, he
shall prepare a report to that effect and forward it along with the
application 6[and the licence (in triplicate) to be granted 7[xxx],
duly completed] to the Central Licence Approving Authority:
PROVIDED that if the Licensing Authority is of the opinion that
the applicant is not in a position to fulfil the requirements laid
down in these rules, he may, by order, for reasons to be recorded
in writing, refuse to grant 8[xxx] the licence, as the case may be.
(4) If on receipt of the application and the report of the Licensing
Authority referred to in sub-rule (3) or after taking such measures
including inspection of the premises by the Inspector, appointed
by the Central Government under section 21 of the Act, with or
without an expert in the concerned field if deemed necessary, the
Central Licence Approving Authority, is satisfied that the applicant
is in a position to fulfil the requirements laid down in these rules,
he may grant or renew the licence, as the case may be:
Provided that if the Central Licence Approving Authority is of the
opinion that the application is not in a position to fulfil the
requirements laid down in these rules, he may, notwithstanding
the report to the Licensing Authority, by order, for reasons to be
recorded in writing, reject the application for grant1 [xxx] of
licence, as the case may be.”
15. We find that, originally the provision was also applicable in case of
‘renewal’ of licenses. However, from all the places where the expression
‘renewal’ or ‘renew’ had originally existed, they were omitted by the
amendment of October 27, 2017, with effect from October 27, 2017. The
only exception being the last line of sub-rule 4 of Rule 68A. In our view,
upon a harmonious construction of the several provisions of Rule 68A,
the omission of the expression ‘renewal’ or ‘renewed’ or ‘renew’ as the
case may be, indicated the intention of the Central Government to
restrict applicability of Rule 68A to grant of license and not renewal
thereof.
16. Part X-B of the said Rules deals with the provisions relating to the
requirements for collection, storage, processing and distribution of whole
human blood, human blood components by blood centres, manufacture
of blood products and collection, processing, testing, storage, banking
and release of umbilical cord blood stem cells. Rule 122F deals with the
form of application for renewal of license for operation of blood centre,
processing of whole human blood for components/ manufacture of blood
products for sale or distribution, collection, processing, testing, storage,
banking and release of umbilical cord blood stem cells. The Rule
provides that the application shall be made to the Licensing Authority
appointed under part VII in Form 27E (in this case) and shall be
accompanied by a license fee of Rs. 6000 and an inspection fee of Rs.
1500 for every inspection thereof for the purpose of renewal of license.
We find that this is the specific provision for renewal of license. Under
the said Rules, the second proviso to Rule 122F(1) is relevant which is
quoted below:“Provided further that a licensee holding a licence in Form 28C, Form
28E or Form 28F as the case may be, for operation of Blood
Centre]/processing
of
whole
human
blood
for
components/manufacture of blood products/collection, processing,
testing, storage, banking and release of umbilical cord blood stem
cells shall apply for grant of licence under sub-rule (1) before the
expiry of the said licence on Form 27-C, Form 27-E or Form 27-F as
the case may be, and he shall continue to operate the same till the
orders on his application are communicated to him.”
17. The Proviso states that, in the event an application for renewal is
pending, the licensee may continue to operate the centre and also the
other activities stated in the said proviso, till the orders on his
application are passed and communicated to him. Rule 122F(5) provides
that if the Licensing Authority is satisfied that the applicant is in a
position to fulfil the requirements laid down in the rules, he shall
prepare a report to that effect and forward it with the application to the
Approving Authority. In the present case, this exercise has been
completed by the Licensing Authority. Rule 122F(5) is quoted below:“122F(5) If the Licensing Authority is satisfied that the applicant is in
a position to fulfil the requirements laid down in the rules, he shall
prepare a report to that effect and forward it along with the
application [and the licence (in triplicate) to be granted or renewed,
duty completed] to the Central Licence Approving Authority:
PROVIDED that if the Licensing Authority is of the opinion that the
applicant is not in a position to fulfil the requirements laid down in
these rules, he may, by order, for reasons to be recorded in writing,
refuse to grant or renew the licence, as the case may be.”
18. The next stage is provided under Rule 122F(6), which is quoted below:“122F(6) If, on receipt of the application and the report of the
licensing authority referred to in sub-rule (5) and after taking such
measures including inspection of the premises, by the Inspector,
appointed by the Central Government under section 21 of the Act,
and/or along with the Expert in the field concerned if deemed
necessary, the Central Licence Approving Authority, is satisfied that
the applicant is in a position to fulfil the requirements laid down in
these rules, he may grant or renew the licence, as the case may be:
PROVIDED that if the Central Licence Approving Authority is of the
opinion that the applicant is not in a position to fulfil the
requirements laid down in these rules he may, notwithstanding the
report of the licensing authority, by order, for reasons to be recorded
in writing, reject the application for grant or renewal of licence, as the
case may be and shall supply the applicant with a copy of the
inspection report.”
19. The aforesaid stage had not arrived when the notice inviting tender was
issued. The appellant sought to participate on the basis of the renewal
granted by the Licensing Authority. The inspection by the Licensing
Authority was complete and satisfactory. The Approving Authority has
neither initiated any inspection nor had made any query with regard to
the ability of the appellant to fulfil the terms and conditions of the rules
and the license. The Approving Authority has kept the matter pending.
In the tender notice, the eligibility criteria provides as follows :“Eligibility Criteria:a) Any Firm/Company should have a valid license for manufacturing
plasma derived products. The firm should furnish attested photocopy
of License for manufacturing plasma derived products approved by
the Licensing Authority.
b) The Firm/Company should furnish the NOC from Drug Controller
General, India for collecting excess/surplus available screened of
Fresh Frozen Plasma (FFP) from licensed blood bank.
c) The firm should have a Plasma Fractionation unit in India of their
own OR any plasma fractionation unit situated in India can be hired
of leased by the firm with submission of authentic documents.
d) Average turnover of the Firm will be Rs.75 (Seventy Five) Crore for
last 3 FYs.
e) The Firm should have minimum 3(three) years of experience in
dealing with plasma fractionation
f) Dealing with govt. sector may be taken as preference
g) The company should have the capacity for fractionation of at least
1,50,000 litre/per year
h) The bidder must be a citizen of India.”
20. We have already discussed that a Licensing Authority has been defined
differently from the Approving Authority. Their role is distinct. We find
that the renewed license was granted by the Licensing Authority. The
contents thereof are quoted below:-
RENEWAL OF DRUG LICENCE IN FORM-28E
***
FORM 26-I
(See Rule 122-I)
Certificate of renewal of licence to manufacture of Blood
Products
1. Certified that Licence no. 02/RR/AP/2013/BP/CC on dated
01/04/2021 in Form 28-E to M/s Ichor Biologics Pvt. Ltd., situated
at Survey No. 222P, Turkapally (V), Shameerpet (M), Medchal
Malkajgiri District, Telangana – 500078, India is here by renewed with
License No. 02/RR/AP/2013/BP/R with effective from 01/04/2026 to
31.03.2031.
2. Name(s) of the items: Products List enclosed with the License.
3. Name(s) of component Technical Staff
(a) Responsible for manufacturing
1. Mr. Manish Aditya G. B. Pharmacy as manufacturing
Chemist
(b) Responsible for Testing
2. Mrs. B. Ramya Sri, M.Sc. Biochemistry as Analytical Chemist
Sd/Dated: 22.06.2026
GANGI SREEN IVAS”
21. The expression used by the authority was that the license is hereby
‘renewed’ with license No. 02/RR/AP/2013/BP/R with effect from April
1, 2026 to March 31, 2031. In our view, the said appellant fulfils the
eligibility criteria. In this connection, Rule 122H is quoted below:“122H. Duration of licence.—An original licence in Form 28C
or Form 28E [or Form 28F] or a renewed licence in Form 26G or
Form 26-I] [or Form 26J] unless sooner suspended or cancelled
shall be valid for a period of five years on and from the date on
which] it is granted or renewed.”
22. It provides that the original license that is issued or renewed under
Form 26(I) will remain valid for 5 years on and from the date on which it
was granted or renewed. Thus, a harmonious reading of the Rules and
the provisions of the Forms would lead us to the conclusion that the
license of the appellant does not become invalid because it is pending
approval before the Approving Authority and shall be deemed to be a
validly issued by virtue of operation of the second proviso of sub-Rule 1
of Rule 122F, till it is either cancelled or revoked or suspended by the
authorities.
23. Tender conditions and eligibility criteria are framed by experts. They are
supposed to know the provisions of law. When they had used the
expression ‘Licensing Authority’ under the eligibility criteria 4(a), in our
opinion, the said expression aligns with the definition of ‘Licensing
Authority’ under Rule 21(b) which has been quoted hereinabove.
24. It is not expected that the tendering authority will not know the
difference in the definition of or in roles and the identities of a Licensing
Authority and the Central License Approving Authority. A writ court
cannot go beyond the terms of the tender. The eligibility criteria of the
tender allows participation of any bidder having a license approved by
the Licensing Authority, meaning thereby, compliance upto the stage of
Rule 122F(5). In this case, the appellant has been disqualified from
participating in the bid, although the law permits the appellant to
continue with the business for the purpose of which the license had
originally been issued and later renewed by the Licensing Authority.
Moreover, endorsement by the Approving Authority without any date is
indicative of the fact that, pending such approval the license validly
issued by the Licensing Authority cannot be treated as invalid. If the
contrary argument is to be accepted, then the validity of the license
would not be from the date of issuance of the same by the Licensing
Authority, but from the date of endorsement by the Approving Authority.
The law does not provide so.
25. Under such circumstances, only on account of delay on the part of the
Approving Authority in approving the renewed license, the appellant
could not be debarred from participating in the financial round. Blood,
blood products, plasma derived products have a limited shelf life. That is
why the proviso was added to Rule 122 F(1). Continuity in the business
is essential so that such rare products which are required to save
human lives, do not go to waste. If the Rules permit the appellant to
continue with such business, then there is no reason why the appellant
cannot participate in a fresh tender process, which is an integral part of
its business activity.
26. Accordingly, the order impugned is set aside. The disqualification of the
appellant at the technical round is also set aside. The financial bid of the
appellant will be opened along with all other financial bids.
27. The appeal and application are disposed of.
28. Urgent Photostat certified copies of this judgment, if applied for, be
supplied to the parties upon fulfilment of requisite formalities.
I Agree
(Arjun Ray Mukherjee, J.)
(Shampa Sarkar, J.)
This page is for informational and research purposes only and does not constitute legal advice.
Consult a qualified advocate for advice specific to your situation.
Is your name in this judgment and should it be masked, or is something on this page wrong?
Request a review